Replimune Group (NASDAQ: REPL) Soars on Citigroup Upgrade and Positive FDA Panel Vote for Melanoma Drug
Citigroup upgraded Replimune Group (NASDAQ: REPL) to Overweight, signaling strong analyst confidence in the biotechnology company . A favorable U.S. Food and Drug Administration (FDA) advisory panel vote backed the company's advanced melanoma drug, RP1, highlighting its potential
- Citigroup upgraded Replimune Group (NASDAQ: REPL) to Overweight, signaling strong analyst confidence in the biotechnology company.
- A favorable U.S. Food and Drug Administration (FDA) advisory panel vote backed the company's advanced melanoma drug, RP1, highlighting its potential in cancer treatment.
- The positive news led to significant stock volatility and a premarket surge, reflecting investor optimism in the pharmaceutical sector.
On July 31, 2026, analyst firm Citigroup upgraded its rating for Replimune Group to Overweight. Replimune Group is a clinical-stage biotechnology company. It focuses on developing new treatments for cancer. The company is working on a drug to treat a specific type of skin cancer called advanced melanoma.
The upgrade occurred when Replimune Group's stock price was $5.41. This positive rating from Citigroup follows significant news from U.S. regulators. The company's stock has seen a wide 52-week price range, from a low of $1.50 to a high of $12.50, showing its market volatility.
This analyst upgrade is supported by a recent favorable vote from a U.S. Food and Drug Administration (FDA) advisory panel. As highlighted by Reuters, Replimune Group shares more than doubled in premarket trading after the panel backed the company's skin cancer drug trial results. The panel voted 10-3 in favor of the therapy.
The committee reviewed the application for Replimune Group's drug, RP1, used with nivolumab. They discussed the reliability of the response rate and the duration of response from the company's IGNYTE study. These clinical trial metrics help determine if a drug is effective and how long its benefits last for patients.
The positive outcome from the FDA advisory meeting is a key step for the company. Despite some concerns raised about the trial's data and design, the panel's vote signals confidence in the treatment's potential for patients with advanced melanoma who have not responded to other therapies.
Originally published by fmp.
View original article
